Sugi Predict

Sugi Predict / Compounds / SCHEMBL283201

SCHEMBL283201

SCHEMBL283201

Cc1ccc(S(=O)(=O)OCCC(F)(F)F)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 2/20 0.42
▸ CA1 P00915 2/20 0.42
▸ CA9 Q16790 2/20 0.42
▸ GAA P10253 1/20 0.41
▸ STAT3 P40763 1/20 0.40
▸ ALDH1A1 P00352 6/20 0.40
▸ CYP3A4 P08684 1/20 0.39
▸ CYP2C9 P11712 1/20 0.39
▸ CYP2C19 P33261 1/20 0.39
▸ KEAP1 Q14145 1/20 0.39
▸ NFE2L2 Q16236 1/20 0.39
▸ PSMD10 O75832 1/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ AGER Q15109 1/20 0.39
▸ BCHE P06276 2/20 0.38
▸ ACHE P22303 2/20 0.38
▸ CA2 P00918 1/20 0.38
▸ CA3 P07451 1/20 0.38
▸ CA6 P23280 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14795273 0.91 ALDH1A1 (0.43) CA12CA1CA9GAASTAT3
SCHEMBL283084 0.90 ALDH1A1 (0.41) CA12CA1CA9GAASTAT3
SCHEMBL30378826 0.90 CA12 (0.42) CA12CA1CA9GAASTAT3
SCHEMBL4049984 0.89 CA12 (0.40) CA12CA1CA9GAASTAT3
SCHEMBL23779385 0.88 CA12 (0.41) CA12CA1CA9GAASTAT3
SCHEMBL9995667 0.87 CA12 (0.40) CA12CA1CA9GAASTAT3
SCHEMBL2535267 0.85 GAA (0.39) CA12CA1CA9GAAALDH1A1
SCHEMBL1502260 0.84 STAT3 (0.44) CA12CA1CA9GAASTAT3
SCHEMBL6002078 0.84 ALDH1A1 (0.43) CA12CA1CA9GAASTAT3
SCHEMBL4128235 0.84 ALDH1A1 (0.41) CA12CA1CA9GAASTAT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4674484-A2 THIENOPYRROLE COMPOUNDS Gilead Sciences, Inc. (US) 2026-01-07 — — EP disclosed
EP-4650351-A1 INHIBITOR OF COMPLEMENT FACTOR B Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. (CN) 2025-11-19 — — EP disclosed
EP-4291562-B1 THIENOPYRROLE COMPOUNDS GILEAD SCIENCES INC (US) 2025-09-10 — — EP disclosed
EP-4581013-A1 TRYPTAMINE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE Cybin IRL Limited (IE) 2025-07-09 — — EP disclosed
US-12122761-B2 2-azaspiro[3.4]octane derivatives as M4 agonists NOVARTIS AG (CH) 2024-10-22 — — US disclosed
US-12100809-B2 Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery MITSUBISHI CHEMICAL CORPORATION (JP) 2024-09-24 — — US disclosed
US-20240217990-A1 THIENOPYRROLE COMPOUNDS GILEAD SCIENCES, INC. 2024-07-04 — — US disclosed
US-20240109905-A1 4-ALKOXY-6-OXO-PYRIDAZINE DERIVATIVES MODULATING NLRP3 JANSSEN PHARMACEUTICA NV (BE) 2024-04-04 — — US disclosed
WO-2024046837-A1 TRYPTAMINE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE CYBIN IRL LIMITED (IE) 2024-03-07 — — WO disclosed
WO-2024018403-A1 SUBSTITUTED IMIDAZOAMIDE COMPOUNDS, AND METHODS USING SAME ARBUTUS BIOPHARMA CORPORATION (CA) 2024-01-25 — — WO disclosed
US-20100069348-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS ABBOTT LABORATORIES (US) 2010-03-18 — — US disclosed
US-20090306110-A1 N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR CHEN ZHAOGEN 2009-12-10 — — US disclosed
EP-2012386-A1 NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE SECONDARY BATTERY Mitsubishi Chemical Corporation (JP) 2009-01-07 — — EP disclosed
EP-1859798-A1 N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR ELI LILLY AND COMPANY (US) 2007-11-28 — — EP disclosed
EP-1379239-B1 N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR LILLY CO ELI (US) 2007-09-12 — — EP disclosed
US-20070099909-A1 N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR CHEN ZHAOGEN 2007-05-03 — — US disclosed
US-7157488-B2 N-(2-Arylethyl) benzylamines as antagonists of the 5-HT6 receptor ELI LILLY AND COMPANY (US) 2007-01-02 — — US disclosed
US-20060009511-A9 N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor CHEN ZHAOGEN 2006-01-12 — — US disclosed
EP-1379239-A2 N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR ELI LILLY AND COMPANY (US) 2004-01-14 — — EP disclosed
WO-2002078693-A2 N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR ELI LILLY AND COMPANY (US) 2002-10-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069348-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS CNR1, CNR2, NPY1R CA12 3556/4885CA1 2702/4885CA9 3500/4885
US-20060009511-A9 N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor HTR6, HTR2C, HTR1B CA12 4818/4885CA1 4137/4885CA9 4699/4885
US-20090306110-A1 N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR HTR6, HTR2C, HTR1B CA12 4818/4885CA1 4137/4885CA9 4699/4885
US-20240217990-A1 THIENOPYRROLE COMPOUNDS SSB, TPMT, LCP2 CA12 4338/4885CA1 4719/4885CA9 4259/4885
US-20240109905-A1 4-ALKOXY-6-OXO-PYRIDAZINE DERIVATIVES MODULATING NLRP3 NLRP3, NLRP1, PYCARD CA12 4868/4885CA1 4831/4885CA9 4873/4885
US-12122761-B2 2-azaspiro[3.4]octane derivatives as M4 agonists CHRM2, CHRM1, CHRM3 CA12 3410/4885CA1 3339/4885CA9 3607/4885
US-20070099909-A1 N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR HTR6, HTR2C, HTR1B CA12 4818/4885CA1 4137/4885CA9 4699/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.